Rupert Vessey, Bristol Myers Squibb head of research and early development
February 6, 2023 09:00 AM ESTUpdated February 10, 02:06 AM
Bioregnum

Up­dat­ed: R&D tur­bu­lence at Bris­tol My­ers now in­cludes the end of a $650M al­liance and the de­par­ture of a top re­search cham­pi­on

This morn­ing biotech Drag­on­fly put out word that Bris­tol My­ers Squibb has hand­ed back all rights to its IL-12 clin­i­cal-stage drug af­ter spend­ing $650 mil­lion to ad­vance it in­to the clin­ic.

The news ar­rives amid a tur­bu­lent R&D stage for the phar­ma gi­ant, which late last week high­light­ed Ru­pert Vessey’s de­ci­sion to de­part this sum­mer as head of ear­ly-stage R&D fol­low­ing a cru­cial three-year stretch af­ter he jumped to Bris­tol My­ers in the big Cel­gene buy­out. Dur­ing that time he struck a se­ries of deals for Bris­tol My­ers, and al­so shep­herd­ed a num­ber of Cel­gene pro­grams down the pipeline, play­ing a ma­jor role for a line­up of biotechs which de­pend­ed on him to cham­pi­on their drugs.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE
TRENDING NOW

Boehringer In­gel­heim touts 10-year plan as it eyes over­tak­ing Bay­er as Ger­many’s largest phar­ma

FDA is ready to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

No­var­tis show­cas­es Ph3 da­ta for Fab­hal­ta in IgAN as FDA grants pri­or­i­ty re­view

J&J says Darza­lex, Carvyk­ti dri­ve Q1 phar­ma sales growth while medtech looms large

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Re­gen­eron en­ters ven­ture in­vest­ing with $500M, poach­es se­nior part­ner from ARCH

A service from the Financial Times